Comparison between survivors and non-survivors (univariable analysis)
| Factors on admission to ICU | Hospital survivors (n=207) | Hospital non-survivors (n=93) | p Value | 180-day survivors*† (n=140) | 180-day non-survivors*† (n=153) | p Value |
|---|---|---|---|---|---|---|
| Age, median (IQR) | 66 (58–73) | 68 (58–75) | 0.62 | 66.5 (59–73.5) | 66 (58–74) | 0.60 |
| Male gender, n (%) | 129 (62) | 56 (60) | 0.87 | 88 (62.9) | 97 (63.4) | 0.90 |
| SOFA Score, median (IQR) | 4 (2–5) | 4 (3–8) | <0.001 | 4 (2–5) | 4 (3–6) | 0.048 |
| APACHE II Score, median (IQR) | 16 (13–20) | 19 (16–25) | <0.001 | 16 (12–20) | 19 (15–23) | 0.001 |
| Metastatic disease, n (%) | 57 (27.5) | 43 (46) | 0.001 | 31 (22) | 69 (45) | <0.001 |
| Confirmed or clinically suspected sepsis, n (%) | 133 (64) | 68 (73) | 0.13 | 87 (62) | 114 (74.5) | 0.03 |
| Neutropenia, n (%) | 8 (3.9) | 9 (9.7) | 0.04 | 6 (4.3) | 11 (7.2) | 0.29 |
| GCS <7, n (%) | 8 (3.9) | 15 (16.1) | <0.001 | 8 (5.7) | 15 (9.8) | 0.19 |
| Number of failed organ systems | ||||||
| 0 OF, n (%) | 86 (41.5) | 26 (28) | <0.001 | 58 (41.4) | 54 (35.3) | 0.24 |
| 1 OF, n (%) | 91 (44) | 34 (36.6) | 58 (41.4) | 64 (41.8) | ||
| 2 OF, n (%) | 19 (9.2) | 17 (18.3) | 18 (12.9) | 18 (11.8) | ||
| 3 OF, n (%) | 11 (5.3) | 11 (11.8) | 9 (6.4) | 12 (7.8) | ||
| >3 OF, n (%) | 0 | 5 (5.4) | 0 | 5 (3.3) | ||
| Need for organ support | ||||||
| Vasopressor/inotrope Rx, n (%) | 32 (15.5) | 27 (29) | 0.006 | 26 (18.6) | 31 (20.3) | 0.83 |
| RRT, n (%) | 11 (5.3) | 13 (14) | 0.01 | 5 (3.6) | 18 (11.8) | 0.009 |
| No ventilatory support, n (%) | 125 (60.4) | 42 (45.2) | 0.043 | 84 (60) | 82 (53.6) | 0.347 |
| Non-invasive ventilation, n (%) | 50 (24.2) | 29 (31.2) | 30 (21.4) | 44 (28.8) | ||
| Mechanical ventilation, n (%) | 32 (15.5) | 22 (23.7) | 26 (18.6) | 27 (17.6) | ||
*Data unavailable for seven patients.
†Including patients who died in hospital.
APACHE, Acute Physiology and Chronic Health Evaluation; GCS, Glasgow Coma Score; ICU, intensive care unit; OF, organ failure; RRT, renal replacement therapy; Rx, treatment; SOFA, sequential organ failure assessment.